---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-127107"
form_type: "8-K"
ticker: "AKTX"
cik: "0001541157"
company_name: "Akari Therapeutics Plc"
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:27:17.571336+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Akari Therapeutics completes merger with Peak Bio, secures $3.2M PIPE and $50M ELOC term sheet

## Summary
- Merger closed; Peak Bio shareholders received 0.2935 Akari ADS per share, representing ~48.4% of combined entity on fully diluted basis.
- Private placement of 1,713,402 ADSs+Warrants at $1.70/unit ($2.385 for insiders) for aggregate gross proceeds of $3.2M.
- Entered term sheet for up to $50M equity line of credit with White Lion Capital over 3 years, subject to registration statement.
- Nasdaq delisting risk resolved; company believes it now meets $2.5M stockholders' equity requirement post-merger.
- Board changes: Wa'el Hashad and Donald Williams resigned; Hoyoung Huh (non-executive chairman), James Neal, Sandip Patel appointed.

## SEC filing metadata
- accession: 0000950170-24-127107
- form_type: 8-K
- ticker: AKTX
- cik: 0001541157
- company_name: Akari Therapeutics Plc
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.01, 3.01, 3.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1541157/000095017024127107/0000950170-24-127107-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1541157/000095017024127107/aktx-20241113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-127107
- JSON: https://secwatch.observer/filing/0000950170-24-127107.json
- Plain text: https://secwatch.observer/filing/0000950170-24-127107.txt

## Key facts
- Executive change
  Sandip Patel was appointed as Director at Akari Therapeutics Plc.
  - Action: appointed
  - Role: Director
  source text: As previously disclosed, effective as of the Effective Time and pursuant to the terms of the Merger Agreement, the Akari Board appointed Hoyoung Huh, M.D., Ph. D, James Neal and Sandip Patel, each of whom were members of the board of directors of Peak Bio, to serve as directors for a term commencing upon the Effective Time.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1541157/000095017024127107/0000950170-24-127107-index.htm
- Executive change
  Wa'el Hashad resigned as Director at Akari Therapeutics Plc.
  - Action: resigned
  - Role: Director
  source text: Wa’el Hashad and Donald Williams resigned as directors of Akari and any committees thereof.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1541157/000095017024127107/0000950170-24-127107-index.htm
- Executive change
  Hoyoung Huh was appointed as non-executive chairman at Akari Therapeutics Plc.
  - Action: appointed
  - Role: non-executive chairman
  source text: Dr. Huh will serve as the non-executive chairman of the Akari Board as of the Effective Time.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1541157/000095017024127107/0000950170-24-127107-index.htm
- Executive change
  Donald Williams resigned as Director at Akari Therapeutics Plc.
  - Action: resigned
  - Role: Director
  source text: Wa’el Hashad and Donald Williams resigned as directors of Akari and any committees thereof.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1541157/000095017024127107/0000950170-24-127107-index.htm
- Executive change
  James Neal was appointed as Director at Akari Therapeutics Plc.
  - Action: appointed
  - Role: Director
  source text: As previously disclosed, effective as of the Effective Time and pursuant to the terms of the Merger Agreement, the Akari Board appointed Hoyoung Huh, M.D., Ph. D, James Neal and Sandip Patel, each of whom were members of the board of directors of Peak Bio, to serve as directors for a term commencing upon the Effective Time.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1541157/000095017024127107/0000950170-24-127107-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.